Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Siemens Healthineers Adds Muscle To Global Antibody Testing Effort, In Talks With Vaccine Developers

Executive Summary

The company now has US emergency use designation for its new SARS-CoV-2 test, which can run on its global installed base of 20,000 analyzers at a current capacity of 50 million tests per month.

You may also be interested in...



Siemens Claims A First With Test That Can Quantify Neutralizing Antibodies To COVID-19

The test measures the relative level of antibodies, which could aid vaccine rollout.

Siemens Lands First FDA OK’s On Tests To Estimate COVID-19 Blood Antibodies

The tests shouldn’t be used as diagnostics, but will give researchers more information about the body’s COVID-19 response.

Antibody Testing During And After The Pandemic: Not All Tests Are Created Equal

While the main role of SARS-CoV-2 antibody testing is currently limited to determining exposure to the virus in populations, the scientific community is working hard to define the neutralizing properties of the antibodies detected, and the duration of the immune response. As a result, antibody testing could be here to stay for the long term for monitoring populations, testing vaccines and selecting patients for trials of a variety of new therapies to treat numerous conditions.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel